Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Phytopharm has received an Orphan Drug status for its Cogane (PYM50028) to treat amyotrophic lateral sclerosis (ALS).
Subscribe to our email newsletter
Cogane is an orally bioavailable neurotrophic factor inducer that crosses the blood-brain barrier and shows neuroprotective effects.
The interim results of Cogane show promising activity in preclinical in vitro and in vivo models of ALS.
The study costs are funded through a UK based charitable organisation – Motor Neurone Disease Association.
A study of Cogane in the genetic in vivo model of ALS is ongoing and the study results are expected in Q4 2011.